Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
772.03
-9.57 (-1.22%)
Mar 10, 2026, 4:00 PM EDT - Market closed
Regeneron Pharmaceuticals Revenue
In the year 2025, Regeneron Pharmaceuticals had annual revenue of $14.34B with 0.99% growth. Regeneron Pharmaceuticals had revenue of $3.88B in the quarter ending December 31, 2025, with 2.51% growth.
Revenue (ttm)
$14.34B
Revenue Growth
+0.99%
P/S Ratio
5.52
Revenue / Employee
$930,753
Employees
15,410
Market Cap
79.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.34B | 140.90M | 0.99% |
| Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
| Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
| Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
| Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
| Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
| Dec 31, 2019 | 6.56B | 1.41B | 27.44% |
| Dec 31, 2018 | 5.15B | -726.60M | -12.37% |
| Dec 31, 2017 | 5.87B | 1.01B | 20.82% |
| Dec 31, 2016 | 4.86B | 756.67M | 18.44% |
| Dec 31, 2015 | 4.10B | 1.28B | 45.55% |
| Dec 31, 2014 | 2.82B | 714.81M | 33.96% |
| Dec 31, 2013 | 2.10B | 726.27M | 52.69% |
| Dec 31, 2012 | 1.38B | 932.65M | 209.20% |
| Dec 31, 2011 | 445.82M | -13.25M | -2.89% |
| Dec 31, 2010 | 459.07M | 79.81M | 21.04% |
| Dec 31, 2009 | 379.27M | 140.81M | 59.05% |
| Dec 31, 2008 | 238.46M | 113.43M | 90.73% |
| Dec 31, 2007 | 125.02M | 61.58M | 97.05% |
| Dec 31, 2006 | 63.45M | -2.75M | -4.15% |
| Dec 31, 2005 | 66.19M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vertex Pharmaceuticals | 12.00B |
| BeOne Medicines AG | 5.34B |
| Incyte | 5.14B |
| argenx SE | 4.25B |
| Alnylam Pharmaceuticals | 3.71B |
| BioNTech SE | 3.70B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
REGN News
- 5 hours ago - Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment - GlobeNewsWire
- 6 hours ago - Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment - GlobeNewsWire
- 17 hours ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 10 days ago - 10 Best CEFs This Month: Average Yield Of 9.7% (February 2026) - Seeking Alpha
- 11 days ago - Why Dupixent Keeps Regeneron A Top Big Pharma Pick - Seeking Alpha
- 11 days ago - Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment - GlobeNewsWire
- 11 days ago - Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment - GlobeNewsWire